104 related articles for article (PubMed ID: 26058984)
1. Characterization of Human Dermal Fibroblasts in Fabry Disease.
Lakomá J; Donadio V; Liguori R; Caprini M
J Cell Physiol; 2016 Jan; 231(1):192-203. PubMed ID: 26058984
[TBL] [Abstract][Full Text] [Related]
2.
Kytidou K; Beekwilder J; Artola M; van Meel E; Wilbers RHP; Moolenaar GF; Goosen N; Ferraz MJ; Katzy R; Voskamp P; Florea BI; Hokke CH; Overkleeft HS; Schots A; Bosch D; Pannu N; Aerts JMFG
J Biol Chem; 2018 Jun; 293(26):10042-10058. PubMed ID: 29674318
[TBL] [Abstract][Full Text] [Related]
3. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients.
Navarro C; Teijeira S; Dominguez C; Fernandez JM; Rivas E; Fachal C; Barrera S; Rodriguez C; Iranzo P
Acta Neuropathol; 2006 Feb; 111(2):178-85. PubMed ID: 16463201
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement in Fabry endothelial cells and fibroblasts: uptake experiments and electron microscopical studies.
Hasholt L; Wandall A; Sørensen SA
Clin Genet; 1988 May; 33(5):360-71. PubMed ID: 2837353
[TBL] [Abstract][Full Text] [Related]
5. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
Yam GH; Zuber C; Roth J
FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
[TBL] [Abstract][Full Text] [Related]
6. Globotriaosylceramide-induced reduction of K
Rickert V; Kramer D; Schubert AL; Sommer C; Wischmeyer E; Üçeyler N
Exp Neurol; 2020 Feb; 324():113134. PubMed ID: 31778662
[TBL] [Abstract][Full Text] [Related]
7. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.
Porto C; Pisani A; Rosa M; Acampora E; Avolio V; Tuzzi MR; Visciano B; Gagliardo C; Materazzi S; la Marca G; Andria G; Parenti G
J Inherit Metab Dis; 2012 May; 35(3):513-20. PubMed ID: 22187137
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants.
Yam GH; Bosshard N; Zuber C; Steinmann B; Roth J
Am J Physiol Cell Physiol; 2006 Apr; 290(4):C1076-82. PubMed ID: 16531566
[TBL] [Abstract][Full Text] [Related]
9. 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality.
Yam GH; Roth J; Zuber C
Biochem Biophys Res Commun; 2007 Aug; 360(2):375-80. PubMed ID: 17592721
[TBL] [Abstract][Full Text] [Related]
10. Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts.
Fuller M; Mellett N; Hein LK; Brooks DA; Meikle PJ
Mol Genet Metab; 2015 Feb; 114(2):268-73. PubMed ID: 25468650
[TBL] [Abstract][Full Text] [Related]
11. Elevated interleukin-8 expression by skin fibroblasts as a potential contributor to pain in women with Fabry disease.
Hofmann L; Grüner J; Klug K; Breyer M; Klein T; Hochheimer V; Wagenhäuser L; Wischmeyer E; Üçeyler N
PLoS One; 2024; 19(4):e0300687. PubMed ID: 38593151
[TBL] [Abstract][Full Text] [Related]
12. Morphological features of iPS cells generated from Fabry disease skin fibroblasts using Sendai virus vector (SeVdp).
Kawagoe S; Higuchi T; Otaka M; Shimada Y; Kobayashi H; Ida H; Ohashi T; Okano HJ; Nakanishi M; Eto Y
Mol Genet Metab; 2013 Aug; 109(4):386-9. PubMed ID: 23810832
[TBL] [Abstract][Full Text] [Related]
13. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
[TBL] [Abstract][Full Text] [Related]
14. c.376A>G, (p.Ser126Gly) Alpha-Galactosidase A mutation induces ER stress, unfolded protein response and reduced enzyme trafficking to lysosome: Possible relevance in the pathogenesis of late-onset forms of Fabry Disease.
Riillo C; Bonapace G; Moricca MT; Sestito S; Salatino A; Concolino D
Mol Genet Metab; 2023 Nov; 140(3):107700. PubMed ID: 37774431
[TBL] [Abstract][Full Text] [Related]
15. Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of fabry knockout male mice.
Lakomá J; Rimondini R; Donadio V; Liguori R; Caprini M
PLoS One; 2014; 9(10):e108641. PubMed ID: 25337704
[TBL] [Abstract][Full Text] [Related]
16. [Intravital determination of pH gradient between the cytoplasm and lysosomes in human fibroblasts in the normal state and in hereditary storage diseases].
Ivleva TS; Ogloblina TA; Litinskaia LL; Khrust IuR; Vidershaĭn GIa
Biull Eksp Biol Med; 1991 May; 111(5):495-8. PubMed ID: 1953901
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits.
Kanda A; Nakao S; Tsuyama S; Murata F; Kanzaki T
Virchows Arch; 2000 Jan; 436(1):36-42. PubMed ID: 10664160
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model.
Lakomá J; Rimondini R; Ferrer Montiel A; Donadio V; Liguori R; Caprini M
Mol Pain; 2016; 12():. PubMed ID: 27531673
[TBL] [Abstract][Full Text] [Related]
19. Endocytosis of lysosomal alpha-galactosidase A by cultured fibroblasts from patients with Fabry disease.
Mayes JS; Cray EL; Dell VA; Scheerer JB; Sifers RN
Am J Hum Genet; 1982 Jul; 34(4):602-10. PubMed ID: 6285697
[TBL] [Abstract][Full Text] [Related]
20. Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology.
Pereira EM; Labilloy A; Eshbach ML; Roy A; Subramanya AR; Monte S; Labilloy G; Weisz OA
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F1015-F1024. PubMed ID: 27681560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
